Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 26274993.
- Also identified by DOI 10.3171/2015.1.JNS142260.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Meningiomas are common intracranial tumors categorized as Grades I-III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Brain Neoplasms
- Meningioma
- Octreotide